We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fiserv (FISV) to Report Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
Fiserv, Inc. is scheduled to report first-quarter 2020 results on May 7, after market close.
While the company’s top line is likely to have benefited from solid segmental performance, the bottom line is expected to have been driven by revenue growth and operational effectiveness.
So far this year, shares of Fiserv have lost 12.2% compared with 10% decline of the industry it belongs to and 12.1% decrease of the Zacks S&P 500 composite.
Let's check out how things have shaped up for the announcement.
Q1 Expectations
The Zacks Consensus Estimate for first-quarter revenues stands at $3.54 billion, indicating year-over-year growth of more than 100%. The top line is likely to have benefited from solid performance of First Data, card services, output solutions and some early network revenue synergy benefits. In fourth-quarter 2019, the company had reported revenues of $4.05 billion.
Revenue growth and operational effectiveness are likely to have boosted Fiserv’s first-quarter 2020 earnings, the Zacks Consensus Estimate for which is pegged at 99 cents per share, indicating year-over-year growth of 17.9%. In fourth-quarter 2019, adjusted earnings per share were $1.13.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for Fiserv this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Fiserv has an Earnings ESP of -1.77% and a Zacks Rank #3.
Here are a few stocks investors may consider from the broader Zacks Business Services sector, as our model shows that these have the right combination of elements to beat on first-quarter 2020 earnings.
Green Dot (GDOT - Free Report) has an Earnings ESP of +3.83% and a Zacks Rank #3. The company is slated to release results on May 11.
ICF International (ICFI - Free Report) has an Earnings ESP of +3.08% and a Zacks Rank #3. The company is slated to release results on May 5.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Shutterstock
Fiserv (FISV) to Report Q1 Earnings: What's in the Cards?
Fiserv, Inc. is scheduled to report first-quarter 2020 results on May 7, after market close.
While the company’s top line is likely to have benefited from solid segmental performance, the bottom line is expected to have been driven by revenue growth and operational effectiveness.
So far this year, shares of Fiserv have lost 12.2% compared with 10% decline of the industry it belongs to and 12.1% decrease of the Zacks S&P 500 composite.
Let's check out how things have shaped up for the announcement.
Q1 Expectations
The Zacks Consensus Estimate for first-quarter revenues stands at $3.54 billion, indicating year-over-year growth of more than 100%. The top line is likely to have benefited from solid performance of First Data, card services, output solutions and some early network revenue synergy benefits. In fourth-quarter 2019, the company had reported revenues of $4.05 billion.
Fiserv, Inc. Revenue (TTM)
Fiserv, Inc. revenue-ttm | Fiserv, Inc. Quote
Revenue growth and operational effectiveness are likely to have boosted Fiserv’s first-quarter 2020 earnings, the Zacks Consensus Estimate for which is pegged at 99 cents per share, indicating year-over-year growth of 17.9%. In fourth-quarter 2019, adjusted earnings per share were $1.13.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for Fiserv this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Fiserv has an Earnings ESP of -1.77% and a Zacks Rank #3.
Fiserv, Inc. Price and EPS Surprise
Fiserv, Inc. price-eps-surprise | Fiserv, Inc. Quote
Stocks to Consider
Here are a few stocks investors may consider from the broader Zacks Business Services sector, as our model shows that these have the right combination of elements to beat on first-quarter 2020 earnings.
ServiceMaster (SERV - Free Report) has an Earnings ESP of +11.24% and a Zacks Rank #3. The company is slated to report results on May 7. You can see the complete list of today’s Zacks #1 Rank stocks here.
Green Dot (GDOT - Free Report) has an Earnings ESP of +3.83% and a Zacks Rank #3. The company is slated to release results on May 11.
ICF International (ICFI - Free Report) has an Earnings ESP of +3.08% and a Zacks Rank #3. The company is slated to release results on May 5.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>